{"transactions":[{"id":1217919,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":82264,"kind":"person","name":"Waltermire Robert E.","position":1,"cik":"0001876996","reported_name":"Waltermire Robert E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior VP, Chief Pharma Dev."}}],"security":"Stock Option (Right to Buy)","published_at":"2025-03-07T22:40:05.000Z","date":"2025-03-05","kind":"grant","planned":false,"acquired":true,"shares":1157,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F13","text":"The option vests as to 25% of the shares on the first anniversary of the date of grant (March 5, 2026) and, thereafter, 6.25% of the shares shall vest on the last day of each successive three-month period, provided the Reporting Person continues in service with the Issuer on each such date."}],"balance_after":1157,"derivative":{"exercise_price":347.28,"expiration_date":"2035-03-05","underlying":"Common Stock","underlying_shares":1157},"source":{"system":"sec-edgar","filing":"0001628280-25-011405","document":"wk-form4_1741387197.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000162828025011405/wk-form4_1741387197.xml","form_type":"4"}},{"id":1217918,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":82264,"kind":"person","name":"Waltermire Robert E.","position":1,"cik":"0001876996","reported_name":"Waltermire Robert E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior VP, Chief Pharma Dev."}}],"security":"Stock Option (Right to Buy)","published_at":"2025-03-07T22:40:05.000Z","date":"2025-03-05","kind":"exercise","planned":false,"acquired":false,"shares":7288,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F12","text":"All shares issued pursuant to the exercise of the options reported herein represent 7,288 shares underlying an overall option award of 12,250 shares. All exercised options had vested. As to the overall option for 12,250 shares, 25% of the shares underlying the option vested on February 24, 2023 and, thereafter, 6.25% of the shares vested, or will vest, on the last day of each successive three-month period, provided the Reporting Person continues in service with the Issuer on each such date."}],"balance_after":3062,"derivative":{"exercise_price":87.09,"expiration_date":"2032-02-22","underlying":"Common Stock","underlying_shares":7288},"source":{"system":"sec-edgar","filing":"0001628280-25-011405","document":"wk-form4_1741387197.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000162828025011405/wk-form4_1741387197.xml","form_type":"4"}},{"id":1217917,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":82264,"kind":"person","name":"Waltermire Robert E.","position":1,"cik":"0001876996","reported_name":"Waltermire Robert E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior VP, Chief Pharma Dev."}}],"security":"Stock Option (Right to Buy)","published_at":"2025-03-07T22:40:05.000Z","date":"2025-03-05","kind":"exercise","planned":false,"acquired":false,"shares":6825,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F11","text":"All shares issued pursuant to the exercise of the options reported herein represent 6,825 shares underlying an overall option award of 35,000 shares. All exercised options had vested. As to the overall option for 35,000 shares, 25% of the shares underlying the option vested on August 2, 2022 and, thereafter, 6.25% of the shares vested, or will vest, on the last day of each successive three-month period, provided the Reporting Person continues in service with the Issuer on each such date."}],"balance_after":4375,"derivative":{"exercise_price":87.92,"expiration_date":"2031-08-02","underlying":"Common Stock","underlying_shares":6825},"source":{"system":"sec-edgar","filing":"0001628280-25-011405","document":"wk-form4_1741387197.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000162828025011405/wk-form4_1741387197.xml","form_type":"4"}},{"id":1217916,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":82264,"kind":"person","name":"Waltermire Robert E.","position":1,"cik":"0001876996","reported_name":"Waltermire Robert E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior VP, Chief Pharma Dev."}}],"security":"Common Stock","published_at":"2025-03-07T22:40:05.000Z","date":"2025-03-05","kind":"grant","planned":false,"acquired":true,"shares":2061,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F10","text":"Represents a grant of restricted stock units, which vest as to 25% of the shares on each of March 5, 2026, March 5, 2027, March 5, 2028 and March 5, 2029, provided the Reporting Person continues in service with the Issuer on each such date."}],"balance_after":5789,"source":{"system":"sec-edgar","filing":"0001628280-25-011405","document":"wk-form4_1741387197.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000162828025011405/wk-form4_1741387197.xml","form_type":"4"}},{"id":1217915,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":82264,"kind":"person","name":"Waltermire Robert E.","position":1,"cik":"0001876996","reported_name":"Waltermire Robert E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior VP, Chief Pharma Dev."}}],"security":"Common Stock","published_at":"2025-03-07T22:40:05.000Z","date":"2025-03-05","kind":"sale","planned":false,"acquired":false,"shares":1412,"price":344.757,"value":486796.884,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F9","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $344.31 to $345.07, inclusive."}],"balance_after":3728,"source":{"system":"sec-edgar","filing":"0001628280-25-011405","document":"wk-form4_1741387197.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000162828025011405/wk-form4_1741387197.xml","form_type":"4"}},{"id":1217914,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":82264,"kind":"person","name":"Waltermire Robert E.","position":1,"cik":"0001876996","reported_name":"Waltermire Robert E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior VP, Chief Pharma Dev."}}],"security":"Common Stock","published_at":"2025-03-07T22:40:05.000Z","date":"2025-03-05","kind":"sale","planned":false,"acquired":false,"shares":4701,"price":343.8479,"value":1616428.9779,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $343.31 to $344.30, inclusive."}],"balance_after":5140,"source":{"system":"sec-edgar","filing":"0001628280-25-011405","document":"wk-form4_1741387197.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000162828025011405/wk-form4_1741387197.xml","form_type":"4"}},{"id":1217913,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":82264,"kind":"person","name":"Waltermire Robert E.","position":1,"cik":"0001876996","reported_name":"Waltermire Robert E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior VP, Chief Pharma Dev."}}],"security":"Common Stock","published_at":"2025-03-07T22:40:05.000Z","date":"2025-03-05","kind":"sale","planned":false,"acquired":false,"shares":1077,"price":342.8967,"value":369299.7459,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $342.30 to $343.29, inclusive."}],"balance_after":9841,"source":{"system":"sec-edgar","filing":"0001628280-25-011405","document":"wk-form4_1741387197.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000162828025011405/wk-form4_1741387197.xml","form_type":"4"}},{"id":1217912,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":82264,"kind":"person","name":"Waltermire Robert E.","position":1,"cik":"0001876996","reported_name":"Waltermire Robert E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior VP, Chief Pharma Dev."}}],"security":"Common Stock","published_at":"2025-03-07T22:40:05.000Z","date":"2025-03-05","kind":"sale","planned":false,"acquired":false,"shares":1043,"price":341.8376,"value":356536.6168,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $341.24 to $342.05, inclusive."}],"balance_after":10918,"source":{"system":"sec-edgar","filing":"0001628280-25-011405","document":"wk-form4_1741387197.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000162828025011405/wk-form4_1741387197.xml","form_type":"4"}},{"id":1217911,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":82264,"kind":"person","name":"Waltermire Robert E.","position":1,"cik":"0001876996","reported_name":"Waltermire Robert E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior VP, Chief Pharma Dev."}}],"security":"Common Stock","published_at":"2025-03-07T22:40:05.000Z","date":"2025-03-05","kind":"sale","planned":false,"acquired":false,"shares":1657,"price":340.7525,"value":564626.8925,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $340.24 to $341.18, inclusive."}],"balance_after":11961,"source":{"system":"sec-edgar","filing":"0001628280-25-011405","document":"wk-form4_1741387197.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000162828025011405/wk-form4_1741387197.xml","form_type":"4"}},{"id":1217910,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":82264,"kind":"person","name":"Waltermire Robert E.","position":1,"cik":"0001876996","reported_name":"Waltermire Robert E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior VP, Chief Pharma Dev."}}],"security":"Common Stock","published_at":"2025-03-07T22:40:05.000Z","date":"2025-03-05","kind":"sale","planned":false,"acquired":false,"shares":400,"price":339.6843,"value":135873.72,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $339.21 to $340.14, inclusive."}],"balance_after":13618,"source":{"system":"sec-edgar","filing":"0001628280-25-011405","document":"wk-form4_1741387197.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000162828025011405/wk-form4_1741387197.xml","form_type":"4"}},{"id":1217909,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":82264,"kind":"person","name":"Waltermire Robert E.","position":1,"cik":"0001876996","reported_name":"Waltermire Robert E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior VP, Chief Pharma Dev."}}],"security":"Common Stock","published_at":"2025-03-07T22:40:05.000Z","date":"2025-03-05","kind":"sale","planned":false,"acquired":false,"shares":1146,"price":338.091,"value":387452.286,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $337.47 to $338.44, inclusive."}],"balance_after":14018,"source":{"system":"sec-edgar","filing":"0001628280-25-011405","document":"wk-form4_1741387197.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000162828025011405/wk-form4_1741387197.xml","form_type":"4"}},{"id":1217908,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":82264,"kind":"person","name":"Waltermire Robert E.","position":1,"cik":"0001876996","reported_name":"Waltermire Robert E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior VP, Chief Pharma Dev."}}],"security":"Common Stock","published_at":"2025-03-07T22:40:05.000Z","date":"2025-03-05","kind":"sale","planned":false,"acquired":false,"shares":1777,"price":336.7795,"value":598457.1715,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $336.445 to $337.44, inclusive."}],"balance_after":15164,"source":{"system":"sec-edgar","filing":"0001628280-25-011405","document":"wk-form4_1741387197.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000162828025011405/wk-form4_1741387197.xml","form_type":"4"}},{"id":1217907,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":82264,"kind":"person","name":"Waltermire Robert E.","position":1,"cik":"0001876996","reported_name":"Waltermire Robert E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior VP, Chief Pharma Dev."}}],"security":"Common Stock","published_at":"2025-03-07T22:40:05.000Z","date":"2025-03-05","kind":"sale","planned":false,"acquired":false,"shares":900,"price":335.1459,"value":301631.31,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $335.005 to $335.98, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and the footnotes below."}],"balance_after":16941,"source":{"system":"sec-edgar","filing":"0001628280-25-011405","document":"wk-form4_1741387197.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000162828025011405/wk-form4_1741387197.xml","form_type":"4"}},{"id":1217906,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":82264,"kind":"person","name":"Waltermire Robert E.","position":1,"cik":"0001876996","reported_name":"Waltermire Robert E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior VP, Chief Pharma Dev."}}],"security":"Common Stock","published_at":"2025-03-07T22:40:05.000Z","date":"2025-03-05","kind":"exercise","planned":false,"acquired":true,"shares":7288,"price":87.09,"value":634711.92,"ownership":{"direct":true},"balance_after":17841,"source":{"system":"sec-edgar","filing":"0001628280-25-011405","document":"wk-form4_1741387197.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000162828025011405/wk-form4_1741387197.xml","form_type":"4"}},{"id":1217905,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":82264,"kind":"person","name":"Waltermire Robert E.","position":1,"cik":"0001876996","reported_name":"Waltermire Robert E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior VP, Chief Pharma Dev."}}],"security":"Common Stock","published_at":"2025-03-07T22:40:05.000Z","date":"2025-03-05","kind":"exercise","planned":false,"acquired":true,"shares":6825,"price":87.92,"value":600054.0,"ownership":{"direct":true},"balance_after":10553,"source":{"system":"sec-edgar","filing":"0001628280-25-011405","document":"wk-form4_1741387197.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000162828025011405/wk-form4_1741387197.xml","form_type":"4"}},{"id":1230591,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":82264,"kind":"person","name":"Waltermire Robert E.","position":1,"cik":"0001876996","reported_name":"Waltermire Robert E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior VP, Chief Pharma Dev."}}],"security":"Common Stock","published_at":"2025-03-05T02:24:28.000Z","date":"2025-02-28","kind":"sale","planned":false,"acquired":false,"shares":175,"price":341.5491,"value":59771.0925,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $341.52 to $341.57, inclusive."}],"balance_after":3728,"source":{"system":"sec-edgar","filing":"0001628280-25-010224","document":"wk-form4_1741141462.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000162828025010224/wk-form4_1741141462.xml","form_type":"4"}},{"id":1230590,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":82264,"kind":"person","name":"Waltermire Robert E.","position":1,"cik":"0001876996","reported_name":"Waltermire Robert E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior VP, Chief Pharma Dev."}}],"security":"Common Stock","published_at":"2025-03-05T02:24:28.000Z","date":"2025-02-28","kind":"sale","planned":false,"acquired":false,"shares":1052,"price":340.9857,"value":358716.9564,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $340.495 to $341.415, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and the footnote below."}],"balance_after":3903,"source":{"system":"sec-edgar","filing":"0001628280-25-010224","document":"wk-form4_1741141462.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000162828025010224/wk-form4_1741141462.xml","form_type":"4"}},{"id":1294657,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":82264,"kind":"person","name":"Waltermire Robert E.","position":1,"cik":"0001876996","reported_name":"Waltermire Robert E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior VP, Chief Pharma Dev."}}],"security":"Common Stock","published_at":"2025-01-27T22:03:07.000Z","date":"2025-01-24","kind":"sale","planned":false,"acquired":false,"shares":103,"price":335.24,"value":34529.72,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported on this Form 4 represents the number of shares sold by the Issuer on behalf of the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale was automatic and not at the discretion of the Reporting Person."}],"balance_after":4955,"source":{"system":"sec-edgar","filing":"0001628280-25-002655","document":"wk-form4_1738015378.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000162828025002655/wk-form4_1738015378.xml","form_type":"4"}},{"id":1300453,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":82264,"kind":"person","name":"Waltermire Robert E.","position":1,"cik":"0001876996","reported_name":"Waltermire Robert E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior VP, Chief Pharma Dev."}}],"security":"Common Stock","published_at":"2025-01-18T00:08:21.000Z","date":"2025-01-17","kind":"sale","planned":false,"acquired":false,"shares":442,"price":273.41,"value":120847.22,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported on this Form 4 represents the number of shares sold by the Issuer on behalf of the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale was automatic and not at the discretion of the Reporting Person."}],"balance_after":5058,"source":{"system":"sec-edgar","filing":"0001628280-25-001900","document":"wk-form4_1737158894.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000162828025001900/wk-form4_1737158894.xml","form_type":"4"}},{"id":1475878,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":82264,"kind":"person","name":"Waltermire Robert E.","position":1,"cik":"0001876996","reported_name":"Waltermire Robert E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior VP, Chief Pharma Dev."}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-19T01:39:28.000Z","date":"2024-06-14","kind":"exercise","planned":false,"acquired":false,"shares":1900,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"All shares issued pursuant to the exercise of the options reported herein represent 1,900 shares underlying an overall option award of 12,250 shares. All exercised options had vested. As to the overall option for 12,250 shares, 25% of the shares underlying the option vested on February 24, 2023 and, thereafter, 6.25% of the shares vested, or will vest, on the last day of each successive three-month period, provided the Reporting Person continues in service with the Issuer on each such date."}],"balance_after":10350,"derivative":{"exercise_price":87.09,"expiration_date":"2032-02-24","underlying":"Common Stock"},"source":{"system":"sec-edgar","filing":"0000950170-24-075221","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000095017024075221/ownership.xml","form_type":"4"}},{"id":1475877,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":82264,"kind":"person","name":"Waltermire Robert E.","position":1,"cik":"0001876996","reported_name":"Waltermire Robert E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior VP, Chief Pharma Dev."}}],"security":"Common Stock","published_at":"2024-06-19T01:39:28.000Z","date":"2024-06-14","kind":"sale","planned":false,"acquired":false,"shares":1900,"price":280,"value":532000.0,"ownership":{"direct":true},"balance_after":5500,"source":{"system":"sec-edgar","filing":"0000950170-24-075221","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000095017024075221/ownership.xml","form_type":"4"}},{"id":1475876,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":82264,"kind":"person","name":"Waltermire Robert E.","position":1,"cik":"0001876996","reported_name":"Waltermire Robert E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior VP, Chief Pharma Dev."}}],"security":"Common Stock","published_at":"2024-06-19T01:39:28.000Z","date":"2024-06-14","kind":"exercise","planned":false,"acquired":true,"shares":1900,"price":87.09,"value":165471.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All shares issued pursuant to the exercise of the options reported herein represent 1,900 shares underlying an overall option award of 12,250 shares. All exercised options had vested. As to the overall option for 12,250 shares, 25% of the shares underlying the option vested on February 24, 2023 and, thereafter, 6.25% of the shares vested, or will vest, on the last day of each successive three-month period, provided the Reporting Person continues in service with the Issuer on each such date."}],"balance_after":7400,"source":{"system":"sec-edgar","filing":"0000950170-24-075221","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000095017024075221/ownership.xml","form_type":"4"}},{"id":1479522,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":82264,"kind":"person","name":"Waltermire Robert E.","position":1,"cik":"0001876996","reported_name":"Waltermire Robert E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior VP, Chief Pharma Dev."}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-15T01:44:36.000Z","date":"2024-06-12","kind":"exercise","planned":false,"acquired":false,"shares":2000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"All shares issued pursuant to the exercise of the options reported herein represent 2,000 shares underlying an overall option award of 35,000 shares. All exercised options had vested. As to the overall option for 35,000 shares, 25% of the shares underlying the option vested on August 2, 2022 and, thereafter, 6.25% of the shares vested, or will vest, on the last day of each successive three-month period, provided the Reporting Person continues in service with the Issuer on each such date."}],"balance_after":15200,"derivative":{"exercise_price":87.92,"expiration_date":"2031-08-02","underlying":"Common Stock","underlying_shares":2000},"source":{"system":"sec-edgar","filing":"0000950170-24-073969","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000095017024073969/ownership.xml","form_type":"4"}},{"id":1479521,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":82264,"kind":"person","name":"Waltermire Robert E.","position":1,"cik":"0001876996","reported_name":"Waltermire Robert E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior VP, Chief Pharma Dev."}}],"security":"Common Stock","published_at":"2024-06-15T01:44:36.000Z","date":"2024-06-12","kind":"sale","planned":false,"acquired":false,"shares":2000,"price":285,"value":570000.0,"ownership":{"direct":true},"balance_after":5500,"source":{"system":"sec-edgar","filing":"0000950170-24-073969","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000095017024073969/ownership.xml","form_type":"4"}},{"id":1479520,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":82264,"kind":"person","name":"Waltermire Robert E.","position":1,"cik":"0001876996","reported_name":"Waltermire Robert E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior VP, Chief Pharma Dev."}}],"security":"Common Stock","published_at":"2024-06-15T01:44:36.000Z","date":"2024-06-12","kind":"exercise","planned":false,"acquired":true,"shares":2000,"price":87.92,"value":175840.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All shares issued pursuant to the exercise of the options reported herein represent 2,000 shares underlying an overall option award of 35,000 shares. All exercised options had vested. As to the overall option for 35,000 shares, 25% of the shares underlying the option vested on August 2, 2022 and, thereafter, 6.25% of the shares vested, or will vest, on the last day of each successive three-month period, provided the Reporting Person continues in service with the Issuer on each such date."}],"balance_after":7500,"source":{"system":"sec-edgar","filing":"0000950170-24-073969","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000095017024073969/ownership.xml","form_type":"4"}},{"id":1504008,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":82264,"kind":"person","name":"Waltermire Robert E.","position":1,"cik":"0001876996","reported_name":"Waltermire Robert E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior VP, Chief Pharma Dev."}}],"security":"Common Stock","published_at":"2024-05-24T01:36:56.000Z","date":"2024-05-21","kind":"sale","planned":false,"acquired":false,"shares":1036,"price":231.34,"value":239668.24,"ownership":{"direct":true},"balance_after":5500,"source":{"system":"sec-edgar","filing":"0000950170-24-064271","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000095017024064271/ownership.xml","form_type":"4"}},{"id":1671173,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":82264,"kind":"person","name":"Waltermire Robert E.","position":1,"cik":"0001876996","reported_name":"Waltermire Robert E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior VP, Chief Pharma Dev."}}],"security":"Market Stock Unit","published_at":"2024-01-25T22:50:59.000Z","date":"2024-01-23","kind":"grant","planned":false,"acquired":true,"shares":1419,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each market stock unit, which is performance-based, represents the contingent right to receive one share of common stock. The amount reported represents the target number of shares which may be issued upon vesting. The market stock units will vest upon certification concerning the Company's stock price performance measured against biotechnology stock index companies for the entire performance period ending December 31, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Each market stock unit, which is performance-based, represents the contingent right to receive one share of common stock. The amount reported represents the target number of shares which may be issued upon vesting. The market stock units will vest upon certification concerning the Company's stock price performance measured against biotechnology stock index companies for the entire performance period ending December 31, 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Each market stock unit, which is performance-based, represents the contingent right to receive one share of common stock. The amount reported represents the target number of shares which may be issued upon vesting. The market stock units will vest upon certification concerning the Company's stock price performance measured against biotechnology stock index companies for the entire performance period ending December 31, 2026."}],"balance_after":1419,"derivative":{"underlying":"Common Stock","underlying_shares":1419},"source":{"system":"sec-edgar","filing":"0000950170-24-007559","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000095017024007559/ownership.xml","form_type":"4"}},{"id":1671172,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":82264,"kind":"person","name":"Waltermire Robert E.","position":1,"cik":"0001876996","reported_name":"Waltermire Robert E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior VP, Chief Pharma Dev."}}],"security":"Stock Option (Right to Buy)","published_at":"2024-01-25T22:50:59.000Z","date":"2024-01-23","kind":"grant","planned":false,"acquired":true,"shares":2138,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vests as to 25% of the shares on the first anniversary of the date of grant (January 23, 2025) and, thereafter, 6.25% of the shares shall vest on the last day of each successive three month period, provided the Reporting Person continues in service with the Issuer on each such date."}],"balance_after":2138,"derivative":{"exercise_price":229,"expiration_date":"2031-01-23","underlying":"Common Stock","underlying_shares":2138},"source":{"system":"sec-edgar","filing":"0000950170-24-007559","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000095017024007559/ownership.xml","form_type":"4"}},{"id":1671171,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":82264,"kind":"person","name":"Waltermire Robert E.","position":1,"cik":"0001876996","reported_name":"Waltermire Robert E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior VP, Chief Pharma Dev."}}],"security":"Common Stock","published_at":"2024-01-25T22:50:59.000Z","date":"2024-01-23","kind":"grant","planned":false,"acquired":true,"shares":1419,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a grant of restricted stock units, which vest as to 25% of the shares on each of January 23, 2025, January 23, 2026, January 23, 2027 and January 23, 2028, provided the Reporting Person continues in service with the Issuer on each such date."}],"balance_after":6536,"source":{"system":"sec-edgar","filing":"0000950170-24-007559","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000095017024007559/ownership.xml","form_type":"4"}},{"id":1676725,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":82264,"kind":"person","name":"Waltermire Robert E.","position":1,"cik":"0001876996","reported_name":"Waltermire Robert E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior VP, Chief Pharma Dev."}}],"security":"Common Stock","published_at":"2024-01-18T18:45:26.000Z","date":"2024-01-16","kind":"tax_withholding","planned":false,"acquired":false,"shares":550,"price":243.92,"value":134156.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents withholding of shares as payment of the Reporting Person's tax liabilities incident to the vesting of restricted stock units granted to the Reporting Person on January 16, 2023."}],"balance_after":5117,"source":{"system":"sec-edgar","filing":"0000950170-24-005294","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000095017024005294/ownership.xml","form_type":"4"}},{"id":1707706,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":82264,"kind":"person","name":"Waltermire Robert E.","position":1,"cik":"0001876996","reported_name":"Waltermire Robert E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior VP, Chief Pharma Dev."}}],"security":"Stock Option (Right to Buy)","published_at":"2023-12-18T21:30:24.000Z","date":"2023-12-15","kind":"exercise","planned":false,"acquired":false,"shares":2000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"All shares issued pursuant to the exercise of the options reported herein represent 4,000 shares underlying an overall option award of 35,000 shares. All exercised options had vested. As to the overall option for 35,000 shares, 25% of the shares underlying the option vested on August 2, 2022 and, thereafter, 6.25% of the shares vested, or will vest, on the last day of each successive three-month period, provided the Reporting Person continues in service with the Issuer on each such date."}],"balance_after":17200,"derivative":{"exercise_price":87.92,"expiration_date":"2031-08-02","underlying":"Common Stock","underlying_shares":2000},"source":{"system":"sec-edgar","filing":"0000950170-23-071116","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000095017023071116/ownership.xml","form_type":"4"}},{"id":1707705,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":82264,"kind":"person","name":"Waltermire Robert E.","position":1,"cik":"0001876996","reported_name":"Waltermire Robert E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior VP, Chief Pharma Dev."}}],"security":"Stock Option (Right to Buy)","published_at":"2023-12-18T21:30:24.000Z","date":"2023-12-14","kind":"exercise","planned":false,"acquired":false,"shares":2000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"All shares issued pursuant to the exercise of the options reported herein represent 4,000 shares underlying an overall option award of 35,000 shares. All exercised options had vested. As to the overall option for 35,000 shares, 25% of the shares underlying the option vested on August 2, 2022 and, thereafter, 6.25% of the shares vested, or will vest, on the last day of each successive three-month period, provided the Reporting Person continues in service with the Issuer on each such date."}],"balance_after":19200,"derivative":{"exercise_price":87.92,"expiration_date":"2031-08-02","underlying":"Common Stock","underlying_shares":2000},"source":{"system":"sec-edgar","filing":"0000950170-23-071116","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000095017023071116/ownership.xml","form_type":"4"}},{"id":1707704,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":82264,"kind":"person","name":"Waltermire Robert E.","position":1,"cik":"0001876996","reported_name":"Waltermire Robert E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior VP, Chief Pharma Dev."}}],"security":"Common Stock","published_at":"2023-12-18T21:30:24.000Z","date":"2023-12-15","kind":"sale","planned":false,"acquired":false,"shares":1000,"price":241,"value":241000.0,"ownership":{"direct":true},"balance_after":5667,"source":{"system":"sec-edgar","filing":"0000950170-23-071116","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000095017023071116/ownership.xml","form_type":"4"}},{"id":1707703,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":82264,"kind":"person","name":"Waltermire Robert E.","position":1,"cik":"0001876996","reported_name":"Waltermire Robert E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior VP, Chief Pharma Dev."}}],"security":"Common Stock","published_at":"2023-12-18T21:30:24.000Z","date":"2023-12-15","kind":"sale","planned":false,"acquired":false,"shares":1000,"price":236,"value":236000.0,"ownership":{"direct":true},"balance_after":6667,"source":{"system":"sec-edgar","filing":"0000950170-23-071116","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000095017023071116/ownership.xml","form_type":"4"}},{"id":1707702,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":82264,"kind":"person","name":"Waltermire Robert E.","position":1,"cik":"0001876996","reported_name":"Waltermire Robert E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior VP, Chief Pharma Dev."}}],"security":"Common Stock","published_at":"2023-12-18T21:30:24.000Z","date":"2023-12-15","kind":"exercise","planned":false,"acquired":true,"shares":2000,"price":87.92,"value":175840.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All shares issued pursuant to the exercise of the options reported herein represent 4,000 shares underlying an overall option award of 35,000 shares. All exercised options had vested. As to the overall option for 35,000 shares, 25% of the shares underlying the option vested on August 2, 2022 and, thereafter, 6.25% of the shares vested, or will vest, on the last day of each successive three-month period, provided the Reporting Person continues in service with the Issuer on each such date."}],"balance_after":7667,"source":{"system":"sec-edgar","filing":"0000950170-23-071116","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000095017023071116/ownership.xml","form_type":"4"}},{"id":1707701,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":82264,"kind":"person","name":"Waltermire Robert E.","position":1,"cik":"0001876996","reported_name":"Waltermire Robert E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior VP, Chief Pharma Dev."}}],"security":"Common Stock","published_at":"2023-12-18T21:30:24.000Z","date":"2023-12-14","kind":"sale","planned":false,"acquired":false,"shares":1000,"price":232,"value":232000.0,"ownership":{"direct":true},"balance_after":5667,"source":{"system":"sec-edgar","filing":"0000950170-23-071116","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000095017023071116/ownership.xml","form_type":"4"}},{"id":1707700,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":82264,"kind":"person","name":"Waltermire Robert E.","position":1,"cik":"0001876996","reported_name":"Waltermire Robert E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior VP, Chief Pharma Dev."}}],"security":"Common Stock","published_at":"2023-12-18T21:30:24.000Z","date":"2023-12-14","kind":"sale","planned":false,"acquired":false,"shares":1000,"price":233,"value":233000.0,"ownership":{"direct":true},"balance_after":6667,"source":{"system":"sec-edgar","filing":"0000950170-23-071116","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000095017023071116/ownership.xml","form_type":"4"}},{"id":1707699,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":82264,"kind":"person","name":"Waltermire Robert E.","position":1,"cik":"0001876996","reported_name":"Waltermire Robert E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior VP, Chief Pharma Dev."}}],"security":"Common Stock","published_at":"2023-12-18T21:30:24.000Z","date":"2023-12-14","kind":"exercise","planned":false,"acquired":true,"shares":2000,"price":87.92,"value":175840.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All shares issued pursuant to the exercise of the options reported herein represent 4,000 shares underlying an overall option award of 35,000 shares. All exercised options had vested. As to the overall option for 35,000 shares, 25% of the shares underlying the option vested on August 2, 2022 and, thereafter, 6.25% of the shares vested, or will vest, on the last day of each successive three-month period, provided the Reporting Person continues in service with the Issuer on each such date."}],"balance_after":7667,"source":{"system":"sec-edgar","filing":"0000950170-23-071116","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000095017023071116/ownership.xml","form_type":"4"}},{"id":1711193,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":82264,"kind":"person","name":"Waltermire Robert E.","position":1,"cik":"0001876996","reported_name":"Waltermire Robert E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior VP, Chief Pharma Dev."}}],"security":"Stock Option (Right to Buy)","published_at":"2023-12-14T21:30:08.000Z","date":"2023-12-13","kind":"exercise","planned":false,"acquired":false,"shares":2500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"All shares issued pursuant to the exercise of the options reported herein represent 3,800 shares underlying an overall option award of 35,000 shares. All exercised options had vested. As to the overall option for 35,000 shares, 25% of the shares underlying the option vested on August 2, 2022 and, thereafter, 6.25% of the shares vested, or will vest, on the last day of each successive three-month period, provided the Reporting Person continues in service with the Issuer on each such date."}],"balance_after":21200,"derivative":{"exercise_price":87.92,"expiration_date":"2031-08-02","underlying":"Common Stock","underlying_shares":2500},"source":{"system":"sec-edgar","filing":"0000950170-23-070416","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000095017023070416/ownership.xml","form_type":"4"}},{"id":1711192,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":82264,"kind":"person","name":"Waltermire Robert E.","position":1,"cik":"0001876996","reported_name":"Waltermire Robert E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior VP, Chief Pharma Dev."}}],"security":"Stock Option (Right to Buy)","published_at":"2023-12-14T21:30:08.000Z","date":"2023-12-12","kind":"exercise","planned":false,"acquired":false,"shares":1300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"All shares issued pursuant to the exercise of the options reported herein represent 3,800 shares underlying an overall option award of 35,000 shares. All exercised options had vested. As to the overall option for 35,000 shares, 25% of the shares underlying the option vested on August 2, 2022 and, thereafter, 6.25% of the shares vested, or will vest, on the last day of each successive three-month period, provided the Reporting Person continues in service with the Issuer on each such date."}],"balance_after":23700,"derivative":{"exercise_price":87.92,"expiration_date":"2031-08-02","underlying":"Common Stock","underlying_shares":1300},"source":{"system":"sec-edgar","filing":"0000950170-23-070416","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000095017023070416/ownership.xml","form_type":"4"}},{"id":1711191,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":82264,"kind":"person","name":"Waltermire Robert E.","position":1,"cik":"0001876996","reported_name":"Waltermire Robert E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior VP, Chief Pharma Dev."}}],"security":"Common Stock","published_at":"2023-12-14T21:30:08.000Z","date":"2023-12-13","kind":"sale","planned":false,"acquired":false,"shares":1000,"price":226,"value":226000.0,"ownership":{"direct":true},"balance_after":5667,"source":{"system":"sec-edgar","filing":"0000950170-23-070416","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000095017023070416/ownership.xml","form_type":"4"}},{"id":1711190,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":82264,"kind":"person","name":"Waltermire Robert E.","position":1,"cik":"0001876996","reported_name":"Waltermire Robert E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior VP, Chief Pharma Dev."}}],"security":"Common Stock","published_at":"2023-12-14T21:30:08.000Z","date":"2023-12-13","kind":"sale","planned":false,"acquired":false,"shares":1500,"price":225,"value":337500.0,"ownership":{"direct":true},"balance_after":6667,"source":{"system":"sec-edgar","filing":"0000950170-23-070416","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000095017023070416/ownership.xml","form_type":"4"}},{"id":1711189,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":82264,"kind":"person","name":"Waltermire Robert E.","position":1,"cik":"0001876996","reported_name":"Waltermire Robert E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior VP, Chief Pharma Dev."}}],"security":"Common Stock","published_at":"2023-12-14T21:30:08.000Z","date":"2023-12-13","kind":"exercise","planned":false,"acquired":true,"shares":2500,"price":87.92,"value":219800.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All shares issued pursuant to the exercise of the options reported herein represent 3,800 shares underlying an overall option award of 35,000 shares. All exercised options had vested. As to the overall option for 35,000 shares, 25% of the shares underlying the option vested on August 2, 2022 and, thereafter, 6.25% of the shares vested, or will vest, on the last day of each successive three-month period, provided the Reporting Person continues in service with the Issuer on each such date."}],"balance_after":8167,"source":{"system":"sec-edgar","filing":"0000950170-23-070416","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000095017023070416/ownership.xml","form_type":"4"}},{"id":1711188,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":82264,"kind":"person","name":"Waltermire Robert E.","position":1,"cik":"0001876996","reported_name":"Waltermire Robert E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior VP, Chief Pharma Dev."}}],"security":"Common Stock","published_at":"2023-12-14T21:30:08.000Z","date":"2023-12-12","kind":"sale","planned":false,"acquired":false,"shares":800,"price":219,"value":175200.0,"ownership":{"direct":true},"balance_after":5667,"source":{"system":"sec-edgar","filing":"0000950170-23-070416","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000095017023070416/ownership.xml","form_type":"4"}},{"id":1711187,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":82264,"kind":"person","name":"Waltermire Robert E.","position":1,"cik":"0001876996","reported_name":"Waltermire Robert E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior VP, Chief Pharma Dev."}}],"security":"Common Stock","published_at":"2023-12-14T21:30:08.000Z","date":"2023-12-12","kind":"sale","planned":false,"acquired":false,"shares":500,"price":216,"value":108000.0,"ownership":{"direct":true},"balance_after":6467,"source":{"system":"sec-edgar","filing":"0000950170-23-070416","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000095017023070416/ownership.xml","form_type":"4"}},{"id":1711186,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":82264,"kind":"person","name":"Waltermire Robert E.","position":1,"cik":"0001876996","reported_name":"Waltermire Robert E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior VP, Chief Pharma Dev."}}],"security":"Common Stock","published_at":"2023-12-14T21:30:08.000Z","date":"2023-12-12","kind":"exercise","planned":false,"acquired":true,"shares":1300,"price":87.92,"value":114296.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All shares issued pursuant to the exercise of the options reported herein represent 3,800 shares underlying an overall option award of 35,000 shares. All exercised options had vested. As to the overall option for 35,000 shares, 25% of the shares underlying the option vested on August 2, 2022 and, thereafter, 6.25% of the shares vested, or will vest, on the last day of each successive three-month period, provided the Reporting Person continues in service with the Issuer on each such date."}],"balance_after":6967,"source":{"system":"sec-edgar","filing":"0000950170-23-070416","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000095017023070416/ownership.xml","form_type":"4"}},{"id":1980199,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":82264,"kind":"person","name":"Waltermire Robert E.","position":1,"cik":"0001876996","reported_name":"Waltermire Robert E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior VP, Chief Pharma Dev."}}],"security":"Stock Option (Right to Buy)","published_at":"2023-03-02T21:30:31.000Z","date":"2023-03-01","kind":"exercise","acquired":false,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"All shares issued pursuant to the exercise of the options reported herein represent 10,000 shares underlying an overall option award of 35,000 shares. All exercised options had vested. As to the overall option for 35,000 shares, 25% of the shares underlying the option vested on August 2, 2022 and, thereafter, 6.25% of the shares vested, or will vest, on the last day of each successive three-month period, provided the Reporting Person continues in service with the Issuer on each such date."}],"balance_after":25000,"derivative":{"exercise_price":87.92,"expiration_date":"2031-08-02","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0000899243-23-006751","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000089924323006751/doc4.xml","form_type":"4"}},{"id":1980198,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":82264,"kind":"person","name":"Waltermire Robert E.","position":1,"cik":"0001876996","reported_name":"Waltermire Robert E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior VP, Chief Pharma Dev."}}],"security":"Stock Option (Right to Buy)","published_at":"2023-03-02T21:30:31.000Z","date":"2023-02-28","kind":"exercise","acquired":false,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"All shares issued pursuant to the exercise of the options reported herein represent 10,000 shares underlying an overall option award of 35,000 shares. All exercised options had vested. As to the overall option for 35,000 shares, 25% of the shares underlying the option vested on August 2, 2022 and, thereafter, 6.25% of the shares vested, or will vest, on the last day of each successive three-month period, provided the Reporting Person continues in service with the Issuer on each such date."}],"balance_after":30000,"derivative":{"exercise_price":87.92,"expiration_date":"2031-08-02","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0000899243-23-006751","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000089924323006751/doc4.xml","form_type":"4"}},{"id":1980197,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":82264,"kind":"person","name":"Waltermire Robert E.","position":1,"cik":"0001876996","reported_name":"Waltermire Robert E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior VP, Chief Pharma Dev."}}],"security":"Common Stock","published_at":"2023-03-02T21:30:31.000Z","date":"2023-03-01","kind":"sale","acquired":false,"shares":100,"price":276.19,"value":27619.0,"ownership":{"direct":true},"balance_after":5667,"source":{"system":"sec-edgar","filing":"0000899243-23-006751","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000089924323006751/doc4.xml","form_type":"4"}},{"id":1980196,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":82264,"kind":"person","name":"Waltermire Robert E.","position":1,"cik":"0001876996","reported_name":"Waltermire Robert E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior VP, Chief Pharma Dev."}}],"security":"Common Stock","published_at":"2023-03-02T21:30:31.000Z","date":"2023-03-01","kind":"sale","acquired":false,"shares":1300,"price":275.53,"value":358189.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $275.18 to $276.18, inclusive."}],"balance_after":5767,"source":{"system":"sec-edgar","filing":"0000899243-23-006751","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000089924323006751/doc4.xml","form_type":"4"}},{"id":1980195,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":82264,"kind":"person","name":"Waltermire Robert E.","position":1,"cik":"0001876996","reported_name":"Waltermire Robert E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior VP, Chief Pharma Dev."}}],"security":"Common Stock","published_at":"2023-03-02T21:30:31.000Z","date":"2023-03-01","kind":"sale","acquired":false,"shares":1672,"price":274.57,"value":459081.04,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $274.06 to $274.99, inclusive."}],"balance_after":7067,"source":{"system":"sec-edgar","filing":"0000899243-23-006751","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000089924323006751/doc4.xml","form_type":"4"}},{"id":1980194,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":82264,"kind":"person","name":"Waltermire Robert E.","position":1,"cik":"0001876996","reported_name":"Waltermire Robert E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior VP, Chief Pharma Dev."}}],"security":"Common Stock","published_at":"2023-03-02T21:30:31.000Z","date":"2023-03-01","kind":"sale","acquired":false,"shares":1928,"price":273.44,"value":527192.32,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $273.00 to $274.00, inclusive."}],"balance_after":8739,"source":{"system":"sec-edgar","filing":"0000899243-23-006751","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000089924323006751/doc4.xml","form_type":"4"}},{"id":1980193,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":82264,"kind":"person","name":"Waltermire Robert E.","position":1,"cik":"0001876996","reported_name":"Waltermire Robert E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior VP, Chief Pharma Dev."}}],"security":"Common Stock","published_at":"2023-03-02T21:30:31.000Z","date":"2023-03-01","kind":"exercise","acquired":true,"shares":5000,"price":87.92,"value":439600.0,"ownership":{"direct":true},"balance_after":10667,"source":{"system":"sec-edgar","filing":"0000899243-23-006751","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000089924323006751/doc4.xml","form_type":"4"}},{"id":1980192,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":82264,"kind":"person","name":"Waltermire Robert E.","position":1,"cik":"0001876996","reported_name":"Waltermire Robert E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior VP, Chief Pharma Dev."}}],"security":"Common Stock","published_at":"2023-03-02T21:30:31.000Z","date":"2023-02-28","kind":"sale","acquired":false,"shares":4100,"price":272.3,"value":1116430.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $271.82 to $272.77, inclusive."}],"balance_after":5667,"source":{"system":"sec-edgar","filing":"0000899243-23-006751","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000089924323006751/doc4.xml","form_type":"4"}},{"id":1980191,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":82264,"kind":"person","name":"Waltermire Robert E.","position":1,"cik":"0001876996","reported_name":"Waltermire Robert E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior VP, Chief Pharma Dev."}}],"security":"Common Stock","published_at":"2023-03-02T21:30:31.000Z","date":"2023-02-28","kind":"sale","acquired":false,"shares":900,"price":271.03,"value":243927.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $270.58 to $271.47, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and the footnotes below."}],"balance_after":9767,"source":{"system":"sec-edgar","filing":"0000899243-23-006751","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000089924323006751/doc4.xml","form_type":"4"}},{"id":1980190,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":82264,"kind":"person","name":"Waltermire Robert E.","position":1,"cik":"0001876996","reported_name":"Waltermire Robert E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior VP, Chief Pharma Dev."}}],"security":"Common Stock","published_at":"2023-03-02T21:30:31.000Z","date":"2023-02-28","kind":"exercise","acquired":true,"shares":5000,"price":87.92,"value":439600.0,"ownership":{"direct":true},"balance_after":10667,"source":{"system":"sec-edgar","filing":"0000899243-23-006751","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000089924323006751/doc4.xml","form_type":"4"}},{"id":2052791,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":82264,"kind":"person","name":"Waltermire Robert E.","position":1,"cik":"0001876996","reported_name":"Waltermire Robert E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior VP, Chief Pharma Dev."}}],"security":"Common Stock","published_at":"2023-01-19T01:00:26.000Z","date":"2023-01-16","kind":"grant","acquired":true,"shares":5667,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a grant of restricted stock units, which vest as to 25% of the shares on each of January 13, 2024, January 13, 2025, January 13, 2026 and January 13, 2027, provided the Reporting Person continues in service with the Issuer on each such date."}],"balance_after":5667,"source":{"system":"sec-edgar","filing":"0000899243-23-002098","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000089924323002098/doc4.xml","form_type":"4"}},{"id":2375353,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":82264,"kind":"person","name":"Waltermire Robert E.","position":1,"cik":"0001876996","reported_name":"Waltermire Robert E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior VP, Chief Pharma Dev."}}],"security":"Call Option","published_at":"2022-02-25T01:17:26.000Z","date":"2022-02-24","kind":"grant","acquired":true,"shares":12250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 25% of the shares on the first anniversary of the date of grant (02/24/2023) and, thereafter, 6.25% of the shares shall vest on the last day of each successive three month period, provided the Reporting Person continues in service with the Issuer on each such date."}],"balance_after":12250,"derivative":{"exercise_price":87.09,"expiration_date":"2022-02-24","underlying":"Common Stock","underlying_shares":12250},"source":{"system":"sec-edgar","filing":"0000899243-22-007774","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000089924322007774/doc4.xml","form_type":"4"}},{"id":2615453,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":82264,"kind":"person","name":"Waltermire Robert E.","position":1,"cik":"0001876996","reported_name":"Waltermire Robert E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior VP, Chief Pharma Dev."}}],"security":"Call Option","published_at":"2021-08-05T01:46:19.000Z","date":"2021-08-02","kind":"grant","acquired":true,"shares":35000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 25% of the shares on the first anniversary of the date of grant (08/02/2022) and, thereafter, 6.25% of the shares shall vest on the last day of each successive three month period, provided the Reporting Person continues in service with the Issuer on each such date."}],"balance_after":35000,"derivative":{"exercise_price":87.92,"expiration_date":"2031-08-02","underlying":"Common Stock","underlying_shares":35000},"source":{"system":"sec-edgar","filing":"0000899243-21-031720","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000089924321031720/doc4.xml","form_type":"4"}}]}